Examples are imatinib, targeting a specific fusion protein of ABL kinase in chronic myeloid leukemia [11], and vemurafenib and dabrafenib, targeting a mutant form of the protein kinase BRAF in metastatic melanoma [12, 13]. The gene discussed is BRAF; the disease is metastatic melanoma.